These payers demonstrate greater flexibility in coverage decisions and faster adoption of new obesity pharmacotherapy compared to public health systems with formal health technology assessment requirements
Brands should not imply that these ingredients help people taking GLP-1 medications maintain muscle unless the claim is supported by evidence that is relevant to GLP-1 users, the finished formulation, and the intended serving size
(The irony is that my 100-pound-heavier self might have qualified for insurance coverage, and current 125-pound me does not.) If you, together with your medical provider, choose to take weight loss drugs, Im here to support you
Stop use and speak with your provider if you experience irritation or a reaction
Retatrutide is a triple agonist peptide for laboratory research, activating GLP-1, GIP, and Glucagon receptors